ArQule Inc. | Mutual Funds
Mutual Funds that own ArQule Inc.
Vanguard Total Stock Market Index Fund
2,532,610
2.33%
441,400
0%
07/31/2018
iShares Russell 2000 ETF
1,816,991
1.67%
-969
0.03%
09/06/2018
Vanguard Extended Market Index Fund
1,010,575
0.93%
224,324
0.01%
07/31/2018
Candriam Equities L - Biotechnology
902,227
0.83%
547,227
0.44%
07/31/2018
iShares Russell 2000 Growth ETF
769,316
0.71%
0
0.04%
09/06/2018
FCP OP Medical BioHe@lth-Trends
641,672
0.59%
0
2.43%
11/30/2017
Vanguard Explorer Fund
328,495
0.3%
328,495
0.01%
06/30/2018
Altshuler Shaham Protected Global Equity
324,512
0.3%
0
3.46%
06/28/2018
Bridgeway Ultra Small Company Market Fund
289,393
0.27%
-150,000
0.44%
12/31/2017
Fidelity Spartan Extended Market Index Fund
272,106
0.25%
0
0.01%
07/31/2018
| Address |
One Wall Street
Burlington Massachusetts 01803
United States
|
|
Employees
|
- |
| Website |
http://www.arqule.com |
| Updated |
07/08/2019 |
| ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. |
